

IN THE CLAIMS:

Claims 28 to 39, added by Amendment filed May 19, 2003, have been renumbered as claims 36 to 47, as set forth below:

1. (Previously Presented) A method for modulating migration of a cell that expresses a galectin-3 receptor comprising contacting the cell with a migration-modulating amount of galectin-3.
2. (Previously Presented) A method for modulating monocyte, neutrophil or macrophage migration comprising contacting a monocyte, neutrophil or macrophage with a migration-modulating amount of galectin-3.
3. (Original) The method of claim 1 or 2, wherein the migration is stimulated.
4. (Original) The method of claim 1 or 2, wherein the migration is inhibited.
5. (Previously Presented) The method of claim 1 or 2, wherein the method uses a subsequence of galectin-3.
6. (Previously Presented) The method of claim 1 or 2, wherein the galectin-3 comprises a fragment thereof.
7. (Original) The method of claim 1 or 2, wherein the migration is modulated in an animal.
8. (Previously Presented) A method for increasing migration of monocytes, neutrophils or macrophages to an inflammatory site comprising contacting the inflammatory site with a migration-increasing amount of galectin-3.
9. (Previously Presented) A method for increasing migration of monocytes, neutrophils or macrophages to a site of infection comprising contacting the infection site with a migration-increasing amount of galectin-3.
10. (Previously Presented) A method for increasing migration of monocytes, neutrophils or macrophages to a tumor comprising contacting the tumor with a migration-increasing amount of galectin-3.
11. (Previously Presented) A method for decreasing migration of monocytes, neutrophils or macrophages to an inflammatory site comprising contacting the inflammatory site with a migration-decreasing amount of galectin-3.
12. (Previously Presented) A method for increasing migration of monocytes, neutrophils or macrophages to a site of infection comprising contacting the infection site with a migration-increasing amount of galectin-3.

13. (Canceled)
14. (Withdrawn) A method for indentifying an agent that modulates galectin-3 mediated cell migration comprising:
 - contacting galectin-3 with a test agent; and
 - detecting galectin-3 mediated cell migration,wherein an alteration of galectin-3 meditated cell migration in the presence of the test agent identifies an agent that modulates galectin-3 mediated cell migration.
15. (Withdrawn) The method of claim 14, wherein the agent increases galectin-3 mediated migration.
16. (Withdrawn) The method of claim 14, wherein the agent decreases galectin-3 mediated migration.
17. (Withdrawn) The method of claim 14, wherein the agent is a small molecule.
18. (Withdrawn) The method of claim 14, wherein the contacting is *in vitro*, intracellular, or *in vivo*.
19. (Withdrawn) A composition comprising an agent identified according to the method of claim 14.
20. (Withdrawn) The composition of claim 19, wherein the agent is a saccharide.
21. (Withdrawn) The composition of claim 20, wherein the saccharide is lactose, galactose, beta-galactoside, or an analog or derivative thereof.
22. (Withdrawn) The composition of claim 19, wherein the composition further comprises a drug.
23. (Withdrawn) A composition comprising a migration-modulating amount of an antibody that specifically binds galectin-3 and a suitable carrier, excipient or diluent.
24. (Withdrawn) A composition comprising a migration-modulating amount of an antibody that specifically binds galectin-3 and a drug.
25. (Withdrawn) A composition comprising a migration-modulating amount of galectin-3 or a functional subsequence thereof and a pharmaceutically acceptable carrier, excipient or diluent.
26. (Withdrawn) The composition of claim 25, wherein the composition further comprises a drug.

27. (Withdrawn) The composition of claim 22, or 24, or 26, wherein the drug is an anti-tumor, antiviral, antibacterial, anti-mycobacterial, anti-fungal, anti-cell proliferative or apoptotic agent.
28. (Withdrawn) A composition comprising galectin-3 or a functional subsequence thereof and an article of manufacture.
29. (Withdrawn) The composition of claim 28, wherein the article of manufacture comprises a dressing.
30. (Withdrawn) The composition of claim 29, wherein the dressing comprises a bandage, a suture, a sponge, or a surgical dressing.
31. (Withdrawn) A microfabricated device containing galectin-3 or a functional subsequence thereof in a pharmaceutically acceptable carrier, said device capable of controlled delivery of the galectin-3 or the functional subsequence.
32. (Withdrawn) The device of claim 31, wherein the device can be implanted in the body of a subject.
33. (Withdrawn) The device of claim 32, wherein the implantation site is a site of infection.
34. (Withdrawn) The device of claim 32, wherein the implantation site is in close proximity to or within a solid tumor.
35. (Withdrawn) The device of claim 32, wherein the implantation site is a site of a lesion.
36. (Previously Presented) A method for modulating migration of a cell that expresses a galectin-3 receptor comprising contacting the cell with a migration-modulating amount of a galectin-3 binding polypeptide, or galectin-3 receptor binding polypeptide.
37. (Previously Presented) A method for modulating monocyte, neutrophil or macrophage migration comprising contacting a monocyte, neutrophil or macrophage with a migration-modulating amount of a galectin-3 binding polypeptide, or galectin-3 receptor binding polypeptide.
38. (Amended) The method of claim [28 or 29] 36 or 37, wherein the migration is stimulated.
39. (Amended) The method of claim [28 or 29] 36 or 37, wherein the migration is inhibited.
40. (Amended) The method of claim [28 or 29] 36 or 37, wherein the method uses a subsequence of galectin-3.

41. (Amended) The method of claim [28 or 29] 36 or 37, wherein the galectin-3 binding polypeptide comprises a galectin-3 antibody or a binding fragment thereof.
42. (Amended) The method of claim [28 or 29] 36 or 37, wherein the migration is modulated in an animal.
43. (Previously Presented) A method for increasing migration of monocytes, neutrophils or macrophages to an inflammatory site comprising contacting the inflammatory site with a migration-increasing amount of a galectin-3 binding polypeptide, or galectin-3 receptor binding polypeptide.
44. (Previously Presented) A method for increasing migration of monocytes, neutrophils or macrophages to a site of infection comprising contacting the infection site with a migration-increasing amount of a galectin-3 binding polypeptide, or galectin-3 receptor binding polypeptide.
45. (Previously Presented) A method for increasing migration of monocytes, neutrophils or macrophages to a tumor comprising contacting the tumor with a migration-increasing amount of a galectin-3 binding polypeptide, or galectin-3 receptor binding polypeptide.
46. (Previously Presented) A method for decreasing migration of monocytes, neutrophils or macrophages to an inflammatory site comprising contacting the inflammatory site with a migration- decreasing amount of a galectin-3 binding polypeptide, or galectin-3 receptor binding polypeptide.
47. (Previously Presented) A method for increasing migration of monocytes, neutrophils or macrophages to a site of infection comprising contacting the infection site with a migration-increasing amount of a galectin-3 binding polypeptide, or galectin-3 receptor binding polypeptide.